Key terms
About ENLV
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ENLV news
Apr 16
8:27am ET
Enlivex Advances Osteoarthritis Trial in Denmark
Apr 16
7:53am ET
Enlivex announces DKMA authorization for Phase I/II trial of allocetra
Apr 12
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Apr 11
8:20am ET
Enlivex Therapeutics announces results of its Phase II trial of Allocetra
Mar 29
5:27pm ET
Enlivex Therapeutics’ Stable Financial Outlook
Feb 15
6:26am ET
Buy Rating Affirmed for Enlivex Amid Promising Clinical Trials and Upcoming Data Readouts
Feb 07
8:13am ET
Enlivex Therapeutics issued U.S. patent covering Allocetra cells
No recent press releases are available for ENLV
ENLV Financials
Key terms
Ad Feedback
ENLV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ENLV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
